Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. Juni 2018 07:00 ET | Quelle: Summit Therapeutics plc

Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint

Ezutromid Development to be DiscontinuedSummit to Focus on Advancing its Pipeline of New Mechanism AntibioticsConference Call Scheduled for 8:00am EDT / 1:00pm BST OXFORD, United Kingdom and...
20. April 2018 07:00 ET | Quelle: Summit Therapeutics plc

Summit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 American Academy of Neurology Annual Meeting

Data show correlation between decreases in muscle damage and reduction in muscle inflammation in patients treated with ezutromid OXFORD, United Kingdom and CAMBRIDGE, Mass., April 20, 2018 (GLOBE...
04. Oktober 2017 07:00 ET | Quelle: Summit Therapeutics PLC

Summit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd WMS Congress

OXFORD, United Kingdom, Oct. 04, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
14. Juni 2017 07:00 ET | Quelle: Summit Therapeutics PLC

Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational Progress

OXFORD, United Kingdom, June 14, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...